Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
Every day we breath thousands of litres of air which contain dust and microbes, such as viruses, fungi and bacteria.
In healthy lungs, mucus lining the airways captures these harmful agents and removes them by being moved along the airways like an escalator. Mucus should be a runny ‘gel’ consisting mainly of water (3% solids & 97% fluid).
In many respiratory diseases the mucus becomes thick and sticky with the solids rising to be as high as 15%. This is due to a lack of fluid and/or an increase in the number of cells that make mucus (secretory cells). The mucus ‘gel’ can no longer be moved – this leads to airways becoming blocked and bacteria and viruses causing severe infections.
Enterprise Therapeutics has two strategies to treat these diseases:
Strategy 1 is to increase the amount of fluid in the airways, thus making the ‘gel’ more runny so it can move and be cleared. This is being achieved by modulating proteins called ion channels that control the amount of water in the airways.
Strategy 2 is to reduce the number of cells that make mucus (secretory cells). Enterprise has identified a drug target which can effectively do this and thus decrease the solid content of the mucus.
Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2020.
Enterprise has developed a pipeline of novel low molecular weight compounds with compound currently in clinical trials.